Scholars Central

Conference abstractPublished 2 Nov 2017

Designing long acting agonists and antagonists of glycoprotein hormones using site directed mutagenesis and gene transfer; from the bench to bedside

Authors: Fuad Fares

University of Haifa, Israel

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Glycoprotein hormones (FSH, LH, hCG and TSH) are a family of heterodimeric proteins composed of two non-covalently linked subunits; Ã?± and Ã?². Glycoproteins are used clinically in the treatment of many diseases. One major issue regarding the clinical use of many peptides is their short half-life due to the rapid clearance from the circulation. To overcome this problem, we succeeded to ligate the signal sequence of O-linked oligosaccharides to the coding sequence of the hormones. The cassette gene that has been used contains the sequence of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin Ã?² (hCGÃ?²) subunit. The CTP contains 28 amino acids with four O-linked oligosaccharide recognition sites. It was postulated that O-linked oligosaccharides add flexibility, hydrophilicity and stability to the protein. On the other hand, it was suggested that the four O-linked oligosaccharides play an important role in preventing plasma clearance and thus increasing the half-life of the protein in circulation. Using this strategy, we succeeded to ligate the CTP to the coding sequence of follitropin (FSH), thyrotropin (TSH), erythropoietin (EPO) growth hormone (GH) and thus to increase the longevity and bioactivity of these proteins in-vivo. Interestingly, the new analogs of FSH and GH were found to be not immunogenic in human and it is already passed successfully clinical trials phase III and phase II, respectively. Moreover, FSH long acting (ELONVA) was approved by the European Commission (EC) for treatment of fertility since 2010. In addition, our results indicated that long acting GH is not toxic in monkeys and the results from clinical trials phase I and phase II seem to be promising. Designing long acting peptides will diminish the cost of these drugs and perhaps reduce the number of injections in the clinical protocols. On the other hand, we found that deletion of N-linked oligosaccharides from hTSH subunits resulted in a significant decrease in bioactivity. Moreover, deglycosylated variants of TSH compete with normal hTSH and human thyroid stimulating immunoglobulin (hTSI) in a dose dependent manner. Thus, this variant, behaves as a potential antagonist, who may offer a novel therapeutic strategy in the treatment of GraveâÂ?Â?s disease, the most common form of hyperthyroidism. In conclusion, it was found that addition of O-linked oligosaccharides or deletion of N-linked oligosaccharides could be interesting strategy for designing new analogs of glycoprotein hormones.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Biotechnology & Biomaterials.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Biotechnology & Biomaterials
  • SubjectBiochemistry & Biotechnology
  • SubjectMaterials Science
  • BylineArticles whose byline prints “Fuad Fares”